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Background: Bromelain is a cysteine protease isolated from pineapple with a range of biological properties in-
cluding platelet aggregation inhibition and anti-inflammatory effects. Recent studies have evaluated the clinical 
implications of bromelain in reducing postoperative inflammatory complications after third molar surgery, but 
the results are contrasting. This systematic review and meta-analysis evaluated the effects of bromelain on health 
outcomes in patients submitted to third molar surgery. 
Material and methods: The study was conducted following the PRISMA statement. Searches were conducted in 
six electronic databases and Google Scholar from inception to May 2018. The following elements were used to 
define eligibility criteria: (1) population: patients undergoing third molar surgery; (2) intervention and controls: 
bromelain vs placebo or no-treatment control group; (3) outcomes: quality of life, postoperative pain, rescue anal-
gesic consumption, facial swelling, and trismus; and (4) study type: randomized clinical trials (RCTs). Treatment 
effects were defined as weighted (WMD) or standardized mean difference (SMD) and 95%CIs. 
Results: Six RCTs were included in the meta-analysis. There was large effect size of bromelain on improving 
physical appearance (SMD -0.77, CI% 95 -1.11 to -0.42), social isolation (SMD -0.97, CI% 95 -1.74 to -0.21), and 
sleep quality (SMD -1.19, CI% 95 -1.97 to -0.40) during the first postoperative week. Differences in pain intensity 
were found during the first 24h (SMD -0.49, CI 95% -0.82 to -0.17) and 7 days after surgery (SMD -0.52, CI 95% 
-0.79 to -0.24). No evidence was found that bromelain was effective in reducing trismus and facial swelling. 
Conclusions: The currently available evidence suggests that bromelain has a beneficial effect in reducing pain and 
has a positive impact on patient quality of life after third molar surgery. However, therapeutic advances for the use 
of bromelain need a high level of evidence and further head-to-head RCTs are needed to inform clinical choices.
Key words: Bromelain, third molar, oral surgical procedures. 
doi:10.4317/medoral.22731
http://dx.doi.org/doi:10.4317/medoral.22731
Mendes MLT, do Nascimento-Júnior EM, Reinheimer DM, Martins-Filho 
PRS. Efficacy of proteolytic enzyme bromelain on health outcomes after 
third molar surgery. Systematic review and meta-analysis of randomized 
clinical trials. Med Oral Patol Oral Cir Bucal. 2019 Jan 1;24 (1):e61-9.   
http://www.medicinaoral.com/medoralfree01/v24i1/medoralv24i1p61.pdf
Article Number: 22731          http://www.medicinaoral.com/
© Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946
eMail:  medicina@medicinaoral.com 
Indexed in: 
Science Citation Index Expanded
Journal Citation Reports
Index Medicus, MEDLINE, PubMed
Scopus, Embase and Emcare 
Indice Médico Español
Med Oral Patol Oral Cir Bucal. 2019 Jan 1;24 (1):e61-9.                 Efficacy of bromelain on health outcomes after third molar surgery. Systematic review and meta-analysis
e62
Introduction
In recent years, evidence has emerged on the efficacy 
of proteolytic enzymes in diverse health-related condi-
tions. Bromelain is a complex natural mixture of pro-
tein-digesting enzymes derived from the fruit or stem 
of pineapple (Ananas cosmosus) used as a phytomedical 
compound with a range of therapeutic benefits (1). It has 
diverse biological properties including platelet aggre-
gation inhibition and anti-inflammatory effects which 
seem to be related to proteolytic activity (2). In addi-
tion, it has been suggested that aqueous extract from the 
crown leaves of pineapple containing bromelain pres-
ents antibacterial and antifungal activities, and presents 
potential use in treating microbial infections (3).
Bromelain is considered to be nontoxic and may be used 
at daily doses of 200 to 2,000 mg/kg, for prolonged pe-
riods of time (4). The degree to which bromelain and its 
components are absorbed and retain function still re-
mains to be elucidated, but studies have suggested that 
oral administration of this proteolytically active pine-
apple extract is absorbed into the intestines and remains 
biologically active with a half-life of ~6–9 h and plasma 
concentration reaching as much as 5,000 pg/ml by 48 h 
after oral multidosing of 3g/day (5). 
Reports from preliminary clinical studies have indicate 
the potential safety and efficacy of bromelain-based 
enzymatic debridement in chronic wounds(6) and deep 
burn injuries (7). In addition, reports have shown that 
anti-inflammatory and analgesic characteristics of 
bromelain could be useful in the treatment of several 
chronic inflammatory disorders as osteoarthritis and 
rheumatoid arthritis (8–10). Recent studies have evalu-
ated the clinical implications of bromelain in reducing 
postoperative inflammatory complications after third 
molar surgery (11,12), but the results are contrasting 
(13). 
Removal of impacted third molars is one of the most 
frequent procedures in oral surgery, but is commonly 
associated to postoperative pain, swelling, and trismus 
(14). These complications are thought to arise from in-
flammatory response which is a direct and immediate 
consequence of the surgical procedure, and may lead 
in patient discomfort and negatively affect their quality 
of life (15). The aim of this study is to perform a sys-
tematic review and meta-analysis to evaluate the effects 
of bromelain on postoperative pain, analgesic consump-
tion, facial swelling, trismus, and quality of life in pa-
tients submitted to third molar surgery. 
Material and Methods
This study was conducted following the Preferred Re-
porting Items for Systematic Reviews and Meta-Analy-
ses statement(16) and supplemented by guidance from 
the Cochrane Collaboration Handbook for System-
atic Reviews of Interventions (17). Institutional review 
board approval and informed consent were not required 
for this systematic review and meta-analysis. 
-Search Strategy
Searches for RCTs were performed in PubMed, Web of 
Science, SCOPUS, Cochrane Central Register of Con-
trolled Trials, and the website ClinicalTrials.gov from 
inception to May 2018. A gray-literature search includ-
ed Google Scholar and OpenThesis. The first 100 results 
of the Google Scholar search were analyzed. The search 
was limited to studies published in full-text versions, 
without language restriction. The reference lists of all 
eligible studies and reviews were scanned to identify 
additional studies for inclusion. The structured search 
strategy used the following terms: (proteolytic enzyme 
OR protease OR proteinase OR bromelin OR brome-
lain) AND (third molar OR third molars OR wisdom 
tooth OR wisdom teeth). To expand the number of eli-
gible articles, there is no use of filters in the search.
-Study Selection and Eligibility Criteria 
Two reviewers (M.L.T.M. and E.M. do N.-J.) indepen-
dently screened the search results and identified studies 
that were potentially relevant based on their title and 
abstract. Relevant studies were read in full text and se-
lected according to eligibility criteria. Disagreements 
between the 2 reviewers were resolved by consensus or 
by a third reviewer (P.R.S.M.-F.).
The following PICOT (Population, Intervention, Com-
parison, Outcomes, Type of study) elements were used 
to define the eligibility criteria: (1) population (patients 
submitted to removal of impacted third molars), (2) 
intervention and comparison (administration of bro-
melain vs placebo or no treatment control group), (3) 
outcomes (primary outcome was quality of life and sec-
ondary outcomes were postoperative pain, rescue anal-
gesic consumption, facial swelling, and trismus), and (4) 
study type (RCTs). Eligible studies must report at least 
1 of the outcomes of interest.  
-Data Extraction and Risk of Bias Assessment
Using a standardized data extraction sheet, the fol-
lowing information from the studies were extracted: 
demographic characteristics of study participants, pre-
operative and postoperative medication, duration of 
follow-up, and outcome data.
Risk of bias was assessed according to the Cochrane 
guidelines for RCTs. Seven domains were assessed for 
evaluation: sequence generation and allocation con-
cealment (selection bias), blinding of participants and 
personnel (performance bias), blinding of outcome 
assessment (detection bias), incomplete outcome data 
(attrition bias), selective outcome reporting (reporting 
bias), and other potential sources of bias. Risk of bias 
was rated as low, unclear, or high according to estab-
lished criteria (17).
Data extraction and risk of bias assessment were per-
formed by two independent reviewers (M.L.T.M. and 
Med Oral Patol Oral Cir Bucal. 2019 Jan 1;24 (1):e61-9.                 Efficacy of bromelain on health outcomes after third molar surgery. Systematic review and meta-analysis
e63
E.M. do N.-J.), and disagreements were resolved by 
consensus or by a third reviewer (P.R.S.M.-F.).
-Data Synthesis
Treatment effects of bromelain on quality of life, pain, 
analgesic consumption, trismus, and facial swelling 
were defined as standardized mean difference (SMD) 
and 95% confidence intervals (CIs). The use of rescue 
medication during the first postoperative week was ana-
lyzed using weighted mean difference (WMD). To cal-
culate the effect sizes, means and standard deviations 
(SD) were obtained for each study group and outcome 
of interest. Differences between groups were meta-ana-
lyzed using the generic inverse-variance method.
Effect size was determined by calculating Cohen’s d 
statistic (18). A value of 0.2 was considered a small ef-
fect, a value of 0.5 a medium effect, and a value of 0.8 
a large effect. A negative effect size indicated that bro-
melain had beneficial effects on short-term outcomes. 
Trismus and facial swelling were analyzed based on 
change-from-baseline measures (19). 
A forest plot was used to present the effect sizes and 
the 95% CIs. A 2-tailed p value < 0.05 was used to de-
termine significance. Statistical heterogeneity was as-
sessed using the Cochran Q test(20) and quantified by 
the I2 index (21). Subgroup analyses were performed 
according to the follow-up time. Leave-one-out sen-
sitivity analysis was performed to evaluate the influ-
ence of control groups (placebo or no treatment control 
group) on effect sizes. Analyses were conducted using 
Review Manager, version 5.3 (Cochrane IMS). 
-Grading the Strength of Evidence
We graded the strength of evidence for the effect of bro-
melain on quality of life and postoperative pain as high, 
moderate, low or very low using the Grading of Recom-
mendations Assessment, Development, and Evaluation 
(GRADE) rating system. In the GRADE system, RCTs 
begin as high-quality evidence but may be lowered by 
1 or more of 5 categories of limitations: risk of bias, 
inconsistency (heterogeneity), indirectness of evidence, 
imprecision, and publication bias (22,23). 
Results
-Data Sources 
Search strategy yielded 493 potentially relevant studies. 
After screening titles and abstracts, 10 full-text articles 
were assessed for eligibility and 6 RCTs (11–13,24–26) 
were included in the meta-analysis. A flow diagram of 
the study selection process and specific reasons for ex-
clusion are detailed in Figure 1.
-Study Characteristics and Risk of Bias Assessment
The total number of patients included in the RCTs was 
312. Most surgical procedures were performed for re-
moval impacted mandibular third molars in healthy 
young adults. In all studies, bromelain was adminis-
tered orally, but there were differences in daily dose fre-
	
Fig. 1: Flow diagram of literature search and screening process.
quency and time of treatment. Paracetamol 500mg was 
prescribed as a rescue medication for pain relief in 4 
studies (11,13,24,25) and analgesic consumption within 
the first postoperative week was included as an outcome 
of interest. 
Postoperative pain was measured using a 10-point visu-
al analogue scale (VAS)(11-13,25) or a 0-4 Likert-type 
scale (26). Trismus was evaluated as maximum interin-
cisal distance (MID) (11,13,24). Measurements of post-
operative swelling were heterogeneous among studies 
and included 3D evaluation (25), 10-point VAS (13), and 
use of facial linear distances (11,12,24). Three studies 
evaluated quality of life during the first postoperative 
week, 2 using the Postoperative Symptom Severity 
(PoSSe) scale (12,24) and one using the Majid scale (11). 
The main characteristics of RCTs are presented in Table 
1. Most studies had unclear risk of bias (Fig. 2).
-Data Synthesis
Quality of life
The meta-analysis evaluating the effect of bromelain on 
quality of life after third molar removal was based on 
results of 3 studies (11,12,24). It was found a moderate 
to large effect size of bromelain on improving eating 
(SMD -0.59, CI% 95 -1.05 to -0.14), physical appear-
ance (SMD -0.77, CI% 95 -1.11 to -0.42), social isolation 
(SMD -0.97, CI% 95 -1.74 to -0.21), and sleep quality 
(SMD -1.19, CI% 95 -1.97 to -0.40) during the first post-
operative week (Fig. 3). 
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Fig. 2: Risk of bias assessment. Footnote: (+) low risk of bias; (-) high 
risk of bias; (?) unclear risk of bias.
	Fig. 3: Forest plot showing the effect of bromelain on quality of life after third molar surgery. 
-Postoperative pain
Five RCTs (11–13,25,26) included in this meta-analysis 
provided sufficient data for pain evaluation during the 
first postoperative week. We found a moderate effect 
size of bromelain in reducing pain. Differences in pain 
intensity were found during the first 24h (SMD -0.49, CI 
95% -0.82 to -0.17, p = 0.003, I2 = 15%) and 7 days after 
surgery (SMD -0.52, CI 95% -0.79 to -0.24, p < 0.001, 
I2 = 0%) (Fig. 4).
-Analgesic consumption
Data on analgesic consumption during the first postop-
erative week was extracted from 4 RCTs(11,24–26). A 
reduction in rescue medication was found among pa-
tients using bromelain compared with control group 
(WMD -0.98, CI 95% -1.81 to -0.15, p = 0.02, I2 = 0%) 
(Fig. 4). 
-Trismus and facial swelling 
Four RCTs(11–13,24) included in these meta-analyses 
provided sufficient information to analyze the effects of 
bromelain on trismus and facial swelling. No evidence 
was found that bromelain was effective in reducing tris-
mus (Fig. 5) and facial swelling (Fig. 5) following third 
molar surgery.
-Sensitivity analysis
To investigate the potential influence of control groups 
on the overall meta-analysis estimation, we omitted one 
study at a time. The “leave-one-out” analysis showed 
that effect sizes did not change substantially with the 
exclusion of any one study.
-Strength of evidence
We graded the effects of bromelain on quality of life 
and pain in patients submitted to third molar surgery as 
moderate quality of evidence as per the GRADE crite-
ria (Table 2).
Discussion
Nonsteroidal anti-inflammatory drugs (NSAIDs) are 
commonly used in the management of short-term out-
comes following third molar surgery (27). Although 
NSAIDs are effective for postoperative pain control, 
gastrointestinal consequences of NSAIDs are signifi-
cant and need to be considered when prescribing this 
group of medications to patients (28). The risk of adverse 
events with traditional NSAIDs has led to the develop-
ment of alternative therapeutic options. Important anti-
inflammatory response without side effects have been 
shown using autologous biomaterial (29), low-level la-
ser therapy (30), and phytotherapy (26).  Bromelain has 
been indicated as a natural alternative to conventional 







	Fig. 4: Efficacy of bromelain on pain (A) and analgesic consumption (B) within the first postoperative week.
treatment with NSAIDs. In this systematic review and 
meta-analysis, we evaluated the efficacy of proteolytic 
enzyme bromelain in reducing postoperative inflamma-
tory complications and its effects on quality of life in 
patients submitted to third molar surgery. 
In this study, we showed that bromelain had a moderate 
effect size in reducing pain during the first 24h and 7 
days after surgery and provided a reduction in the aver-
age number of rescue medication required per patient. 
Although no evidence was found that bromelain was 
effective in reducing trismus and facial swelling, bro-
melain had a moderate to large effect size on improving 
several domains in quality of life (eating, physical ap-
pearance, social isolation, and sleep quality) during the 
first postoperative week. 
It has been shown that bromelain has anti-inflammatory 
effects due to the inactivation of bradykinin in inflamed 
tissues leading in decreased levels of prostaglandin E2 
(PGE2) and substance P (31,32). In addition, brome-
lain seems to play an important role as plasminogen 






Fig. 5: Efficacy of bromelain on trismus (A) and facial swelling (B) within the first postoperative week.






























































































































































































































































































































































































































































































activator leading in decreased levels of serum plasmin 
and increased vascular permeability, which allows the 
edema fluid to reenter the vessels and resolving stasis 
(33). These physiological effects can lead to significant 
reductions in pain and swelling while enhancing circu-
lation to the site of surgery. Although reducing postop-
erative pain and improved in quality of life are achieved 
with bromelain, the results on decreasing facial swell-
ing following third molar surgery are still inconclusive. 
Furthermore, there is striking lack of safety data for 
bromelain and rigorous studies are needed to fully char-
acterize bromelain as therapeutic anti-inflammatory 
agent in surgical care. 
The results of this meta-analysis should be interpreted 
with caution because the pharmacological activities of 
bromelain in each study and effect estimates may have 
been influenced by a range of factors including the num-
ber of active ingredients whose ratio to each other might 
vary according to soil composition, climatic conditions 
during plant growth, variety of pineapple, and manu-
facturing process (2).  In addition, despite commercial-
ly available chemical and nutraceutical preparations of 
bromelain contain predominately stem bromelain (34), 
the method of purification and the source of pineapple 
extract in some studies included in this review is un-
certain. It has been found that stem bromelain contains 
high quantities of protease content when compared with 
bromelain derived from the fruit (5,35). 
Moreover, the studies evaluated in this review co-
prescribed the bromelain along with rescue analgesics 
which may lead to confound drug-effect associations. 
Interestingly, although we found a reduction of pain in 
patients using bromelain, there was a mean decrease of 
only one tablet of analgesic rescue medication during 
the first postoperative week. Pain relief is a subjective 
experience and the results observed for patients using 
bromelain could be explained in part by the placebo 
effect. Optimization of drug prescription and medica-
tion management after surgeries should be an important 
part of clinical decision making but results from head-
to-head trials comparing the anti-inflammatory effect 
of bromelain with and without NSAIDs/analgesics after 
third molar surgery are scarce and a pragmatic recom-
mendation of bromelain cannot be supported. 
The currently available evidence suggests that brome-
lain has a beneficial effect in reducing pain and has 
a positive impact on patient quality of life after third 
molar surgery. However, therapeutic advances for the 
use of bromelain need a high level of evidence and fur-
ther head-to-head RCTs are needed to inform clinical 
choices.
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